文献速递妇科

肿瘤破碎对I期子宫平滑肌肉瘤复发模式及肿瘤学结局的影响

The impact of tumor fragmentation in patients with stage I uterine leiomyosarcoma on patterns of recurrence and oncologic outcome.
PubMed 文献 · Gynecol Oncol · 2020-11-04

本研究回顾性纳入152例I期子宫平滑肌肉瘤患者,比较肿瘤破碎(旋切)与未破碎患者的复发模式和生存结局。结果显示破碎组复发风险显著增高(86.3% vs 67.2%),无进展生存期更短(中位7.3 vs 13.8个月,HR 1.5,P=0.04),且腹膜复发比例更高(63.2% vs 18.1%)。总生存期无显著差异。

要点

  • 肿瘤破碎与I期uLMS复发风险显著升高相关(86.3% vs 67.2%)。
  • 破碎组中位PFS显著缩短(7.3 vs 13.8个月,HR 1.5,P=0.04)。
  • 破碎组腹膜复发比例更高(63.2% vs 18.1%),血行复发比例更低。

核心结论

  • 肿瘤破碎/旋切与I期子宫平滑肌肉瘤复发风险显著增高相关,腹膜复发增加近4倍。
  • 预后生物标志物独立于破碎或治疗,仍对肿瘤学结局有重要预测价值。

研究设计与样本

  • 回顾性队列研究,纳入2000年1月至2019年1月初次手术后3个月内就诊于本机构的I期uLMS患者,排除复发者。
  • 共152例,非破碎组107例(70%)行全子宫切除术无标本破碎记录,破碎组45例(30%)有标本破碎记录。
  • 破碎定义为腹膜腔或阴道内标本手动破碎或旋切(通过电动旋切器或其他方式)。
  • 中位年龄55岁(范围30-91),中位随访42.1个月(范围1.1-197.8)。
  • 40例(26.3%)在本机构行初次手术,112例(73.7%)在外院手术。

主要发现

  • 共110例(72.3%)复发:非破碎组72/107(67.2%),破碎组38/44(86.3%)。
  • 非破碎组 vs 破碎组中位PFS:13.8个月(95%CI 9.2-20.2) vs 7.3个月(95%CI 3-13.1),HR 1.5(95%CI 1.02-2.24),P=0.04。
  • 非破碎组 vs 破碎组中位OS:82.1个月(95%CI 52.4-122) vs 47.8个月(95%CI 28.5-129.6),HR 1.1(95%CI 0.67-1.82),P=0.7。
  • 复发患者中,非破碎组69.4%仅血行部位复发,18.1%仅腹膜复发;破碎组28.9%血行部位复发,63.2%腹膜复发。
  • 种族、淋巴血管浸润、术后化疗与PFS独立相关;核分裂指数与OS独立相关。

临床怎么用

  • 对I期子宫平滑肌肉瘤应避免肿瘤破碎/旋切,以降低复发风险及腹膜复发。
  • 预后生物标志物(如核分裂指数、淋巴血管浸润)可用于风险分层,独立于破碎状态。

局限性

  • 回顾性研究设计,样本量有限(152例),破碎组仅45例。
  • 73.7%患者初次手术在外院,可能存在选择偏倚和信息偏倚。
  • 破碎组中1例复发数据缺失(38/44而非38/45)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To evaluate the impact of tumor fragmentation on oncologic outcomes in patients with stage I uterine leiomyosarcoma (uLMS). METHODS: We identified all patients diagnosed with stage I uLMS presenting to our institution within three months of primary surgery, 1/2000-1/2019. Patients with recurrent disease were excluded. The non-morcellated group had total hysterectomy without documented specimen fragmentation; the morcellated group, total hysterectomy with documented specimen fragmentation. We defined fragmentation as manual fragmentation or morcellation (via power morcellator or otherwise) of the specimen in peritoneal cavity or vagina. Appropriate statistical analyses were performed. RESULTS: 152 patients met inclusion criteria. 107 (70%) underwent total hysterectomy (non-morcellated); 45 (30%) underwent morcellation. Median age at diagnosis for the entire cohort was 55 years (range 30-91). Median follow-up was 42.1 months (range 1.1-197.8). 40 (26.3%) patients had primary surgery at our institution, 112 (73.7%) at an outside hospital. In total 110 (72.3%) recurred: 72/107 (67.2%) non-morcellated; 38/44 (86.3%) morcellated. Median progression-free survival (PFS) for non-morcellated versus morcellated was 13.8 (95%CI 9.2-20.2) versus 7.3 months (95%CI 3-13.1), HR 1.5 (95%CI 1.02-2.24); P = 0.04. Median overall survival (OS) for non-morcellated versus morcellated was 82.1 (95%CI 52.4-122) versus 47.8 months (95%CI 28.5-129.6), HR 1.1 (95%CI 0.67-1.82); P = 0.7. Among patients with recurrence, 69.4% of non-morcellated recurred at hematogenous sites only, 18.1% recurred in peritoneum only; 28.9% of morcellated recurred at hematogenous sites, 63.2% in peritoneum. Race, lymphovascular invasion, postoperative chemotherapy, were independently associated with PFS. Mitotic index was independently associated with OS. CONCLUSIONS: Tumor fragmentation/morcellation was associated with significantly higher risk of recurrence and a nearly 4-fold increase in peritoneal recurrence. Prognostic biomarkers remain important in predicting oncologic outcomes, independent of fragmentation or treatment.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Pedra Nobre S, Hensley ML, So M, et al. The impact of tumor fragmentation in patients with stage I uterine leiomyosarcoma on patterns of recurrence and oncologic outcome. Gynecol Oncol. 2020. PMID: 33158511. doi:10.1016/j.ygyno.2020.10.020

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。